Suggested remit: To appraise the clinical and cost effectiveness of sparsentan within its marketing authorisation for treating primary IgA nephropathy.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6308

Provisional Schedule

Committee meeting 03 October 2024
Expected publication 11 December 2024

Project Team

Project lead Celia Mayers

Email enquiries


Companies sponsors Vifor Pharma (sparsentan)
Others Department of Health and Social Care
  NHS England
Patient carer groups Kidney Care UK
  Kidney Research UK
  National Kidney Federation
  Polycystic Kidney Disease Charity
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Renal Industries
  Association of Renal Technologists
  British and Irish Hypertension Society
  British Association for Nursing in Cardiovascular Care
  British Association of Endocrine and Thyroid Surgeons
  British Association of Urological Nurses
  British Geriatrics Society
  British Heart Foundation
  National Metabolic Biochemistry Network
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for DGH Nephrologists
  Society for Endocrinology
  UK Clinical Pharmacy Association
  UK Kidney Association
  UK Renal Pharmacy Group
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Advanz pharma (acetazolamide, amiloride hydrochloride)
  AstraZeneca (dapagliflozin)
  Atnahs pharma (chlortalidone, lisinopril)
  Aurobindo pharma (amiloride hydrochloride, candesartan, enalapril, fosinopril, irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, valsartan)
  Boehringer Ingelheim (empagliflozin, telmisartan)
  Bristol laboratories (lisinopril)
  Brown & Burk (irbesartan, lisinopril, ramipril, telmisartan, losartan)
  Chemidex pharma (bumetanide)
  Daiichi Sankyo (olmesartan)
  Dexcel pharma (enalapril, losartan)
  Essential pharma (amiloride hydrochloride)
  Genus Pharmaceuticals Holdings Ltd [STADA] (targeted-release budesonide)
  Glenmark pharma (olmesartan, perindopril, telmisartan)
  Ipca laboratories (furosemide)
  Martindale pharma (captopril)
  Menarini Farmaceutica Internazionale SRL (canagliflozin)
  Merck Sharp & Dohme (ertugliflozin)
  Morningside healthcare (chlortalidone)
  Mylan (bendroflumethiazide, bumetanide, candesartan, enalapril, eprosartan, indapamide, irbesartan, lisinopril, losartan, perindopril, torasemide, trandolapril, valsartan, xipamide)
  Neon healthcare (candesartan)
  Novartis (valsartan)
  Organon Pharma (enalapril, losartan)
  Pfizer (quinapril)
  Pinewood healthcare (furosemide)
  Rosemont pharmaceuticals (furosemide, bumetanide, lisinopril, ramipril)
  Sandoz (candesartan, cyclophosphamide, losartan, perindopril, ramipril, telmisartan)
  Sanofi (furosemide, irbesartan, ramipril)
  Servier laboratories (indapamide, perindopril)
  Sigma pharmaceuticals (indapamide)
  Strides pharma (indapamide)
  Takeda (azilsartan)
  Ten pharma (captopril)
  Thame laboratories (captopril, furosemide)
  Thornton & Ross (olmesartan)
  Tillomed laboratories (perindopril, amiloride hydrochloride)
  Zentiva (indapamide, irbesartan, ramipril, valsartan)
Evidence review group School of Health and Related Research (ScHARR)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Kidney and Transplant Group
  Cochrane UK
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  Society for Research in Rehabilitation
  Wellcome Trust


Key events during the development of the guidance:

Date Update
05 March 2024 Invitation to participate
15 September 2023 - 13 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6308
03 August 2023 In progress. DHSC referral received
07 June 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual